Sherman Jeffrey Scott

CFO Sherman Scott buys 20,000 NEO shares at $5.62; stock down -70.5% from 52-week high of $18.61

CFO Sherman Jeffrey Scott purchased 20,000 shares of NEOGENOMICS INC at $5.62 on 2025-08-06, increasing his holdings to 188,332 shares. The transaction occurs against a backdrop of significant stock deterioration: the stock trades at $5.49 currently, down -24.9% over the past 30 days and -32.5% over 90 days, representing a -70.5% decline from its 52-week high of $18.61. His prior buy at this ticker (2025-05-02) yielded -3.0% at 30 days and -35.5% at 90 days, with a zero win rate across his cross-ticker trading history. The company reported negative net income of $-45,092,000.00 against revenue of $181,330,000.00 in the latest quarter, reflecting ongoing unprofitability despite annual revenue growth of +11.6%. The confluence of steep price declines, unprofitable operations, and a poor timing pattern on his prior transaction at this same ticker warrants scrutiny of the underlying business trajectory.

CFO Sherman Scott purchases 20,000 NEO shares at $7.51; joins cluster of 3 insiders buying within 14 days amid -45.4% 90-day decline and -$25.9M recent-quarter loss.

Sherman Jeffrey Scott, serving as Chief Financial Officer, purchased 20,000 shares at $7.51 on 2025-05-02, expanding his holdings from 138,5K to 158.5K shares. The purchase occurs against a backdrop of significant recent weakness: NEO has declined 45.4% over the past 90 days and 12.4% over the past 30 days, now trading at $7.69 versus a 52-week high of $18.61. The company reported a net loss of $25.9M in its latest quarter despite 11.6% annual revenue growth, and maintains unprofitability on a full-year basis. Notably, three other insiders also bought within the past 14 days, establishing a cluster buy pattern that suggests coordinated conviction at these lower price levels. This convergence of insider accumulation during a sustained drawdown in an unprofitable business warrants investor attention to the drivers behind management's posture.